Zacks Investment Research cut shares of Eisai Co., Ltd (NASDAQ:ESALY) from a buy rating to a sell rating in a research note released on Tuesday.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

Eisai Co. (NASDAQ:ESALY) opened at 62.82 on Tuesday. The stock has a market capitalization of $17.96 billion and a P/E ratio of 26.13. The company has a 50 day moving average of $61.45 and a 200-day moving average of $60.39. Eisai Co. has a one year low of $53.55 and a one year high of $67.60.

5 Day Chart for NASDAQ:ESALY

Receive News & Stock Ratings for Eisai Co. Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai Co. Ltd and related stocks with our FREE daily email newsletter.